Search Results - "Vega, E Chamorro de"

Hepatitis C virus infection and the role of a pharmaceutical care program by Chamorro-de-Vega, E, Rodríguez-González, C G, Giménez-Manzorro, Álvaro, Herranz, A, Sanjurjo, M

“…Abstract Purpose The design, implementation, and assessment of a comprehensive pharmaceutical care program (CPCP) for hepatitis C virus (HCV)-infected patients…”
Get full text

CP-163 Onco-haematological outpatients treated with oral antineoplastic agents: pharmacist interventions by Escudero-Vilaplana, V, Collado-Borrell, R, Giménez-Manzorro, A, Ortega-Navarro, C, de Vega, E Chamorro, Ruiz-Martínez, C, Rodríguez-González, C, Herranz-Alonso, A, Sanjurjo-Sáez, M

“…BackgroundCurrently, oral antineoplastic agents (OAA) represent approximately 40% of all chemotherapy agents. Thus, onco-haematological outpatients have…”
Get full text

CP-212 Effectiveness and safety of new direct acting antivirals for the treatment of hepatitis C infection: Preliminary data in a coinfected HIV/HCV population by Rodriguez-Gonzalez, CG, Vega, E Chamorro-De, Gimenez-Manzorro, A, Ruiz-Martinez, C, Marzal-Alfaro, B, Collado-Borrell, R, Sarobe-Gonzalez, C, Revuelta-Herrero, JL, Herranz-Alonso, A, Sanjurjo-Saez, M

“…BackgroundIn 2015, the development of well tolerated and highly effective direct acting antivirals (DAAs) for hepatitis C virus (HCV) dramatically changed the…”
Get full text

DI-054 Safety results of direct acting antivirals for the treatment of hepatitis C virus infection by Lallana-Sáinz, E, Giménez-Manzorro, A, Ruiz-Martínez, C, Vega, E Chamorro de, Ribed, A, Alfaro, B Marzal, Sarobe-González, C, Tovar-Pozo, M, Herranz-Alonso, A, Sanjurjo-Sáez, M

“…BackgroundThe recent development of new drugs has changed radically the treatment of chronic hepatitis C virus (HCV) infection, from interferon (IFN) based…”
Get full text

CP-119 Questions about the new direct acting antiviral agents by Marquez, AM Gomez, de Vega, E Chamorro, Manzorro, A Gimenez, Gonzalez, C Rodriguez, Rodriguez, S Manrique, Jimenez, R Romero, Fernandez-Llamazares, C Martinez, Pozo, M Tovar, Alonso, A Herranz, Saez, M Sanjurjo

“…BackgroundThe marketing of direct acting antiviral agents (DAAs) has meant a great revolution in the treatment of chronic hepatitis C virus (HCV) infection…”
Get full text

P646 Clinical decision support in the prevention of adverse effects associated with immunosuppressive drugs in patients with Inflammatory Bowel Disease by Lobato Matilla, M E, Marin Jimenez, I, Menchén Viso, L A, Miranda Bautista, J, Chamorro de Vega, E, Romero Jiménez, R, Ferris Villanueva, M, Herranz Alonso, A, Sanjurjo Sáez, M

Get full text

5PSQ-119 A new pharmaceutical care programme for COVID-19 patients treated with Paxlovid®: Implementation and safety outcomes reported by Ferris Villanueva, M, Chamorro de Vega, E, Gonzalez Rodriguez, CG, Torroba Sanz, B, Vicente Valor, J, Herranz Alonso, A, Sanjurjo Sáez, M

“…Background and ImportanceThe COVID-19 pandemic has highlighted the important role that hospital pharmacists play in improving pharmacotherapy outcomes…”
Get full text

4CPS-045 Healthcare evaluation of hospital pharmacy services by patients with immune-mediated inflammatory diseases: a multicentre study by Calvo García, A, Escudero Vilaplana, V, Ramirez Herraiz, E, Hernandez Muniesa, B, Pacheco Garcia-Valdecasas, M Fernández, Romero Jiménez, R, Chamorro De Vega, E, Herrero Muñoz, N, Ubeda Ruiz, B, Morell Baladron, A

“…Background and importanceImmune-mediated inflammatory diseases (IMIDs) are a group of disabling chronic diseases.Aim and objectivesTo assess the satisfaction…”
Get full text

4CPS-238 Evaluation of effectiveness of compounded oral vancomycin capsules for treatment of Clostridium difficile infection by Moraza, Á Narrillos, Pernía López, MS, Olmedo Samperio, M, Chamorro De Vega, E, Rodriguez Gonzalez, C, Vicente Valor, J, Somoza Fernández, B, Ruiz Briones, P, Herranz Alonso, A, Sanjurjo Saez, M

“…Background and importanceOral vancomycin (125 mg four times daily) is the standard treatment for mild/moderate Clostridium difficile infection (CDI). As there…”
Get full text

5PSQ-134 Analysis of factors related to the clinical course of COVID-19 infection in patients with hypertension by Garcia Moreno, FJ, Chamorro De Vega, E, Rodriguez Gonzalez, C, Melgarejo Ortuño, A, Vicente Valor, J, Somoza Fernandez, B, Taladriz Sender, I, Villanueva Bueno, C, De Lorenzo Pinto, A, Herranz Alonso, A, Sanjurjo Saez, M

“…Background and importanceIdentification of the angiotensin converting enzyme (ACE2) as a target of the SARS-CoV-2 virus raises questions about a possible…”
Get full text

4CPS-329 Do patients with immune mediated inflammatory diseases think they know their medication? by Melgarejo-Ortuño, A, Romero Jiménez, RM, Chamorro De Vega, E, Ais Larisgoitia, A, Lobato Matilla, ME, García Sánchez, S, Narrillos Moraza, A, Herranz Alonso, A, Sanjurjo Saez, M

“…Background and importancePatients with immune mediated inflammatory diseases (IMID) have complex treatment. This is due to biological treatments, other chronic…”
Get full text

5PSQ-033 Effectiveness of computerised decision support system-based intervention in antimicrobial use: the HIGEA project by Rodriguez-Gonzalez, CG, Chamorro-de Vega, E, Ibañez-Garcia, S, Martin-Barbero, ML, de la Rosa, JL, Herranz-Alonso, A, Sanjurjo-Saez, M

“…BackgroundClinical decision support systems (CDSS) can play an important role in facilitating antimicrobial stewardship programmes (ASP). However, the effects…”
Get full text

6ER-007 Off-label use of dalbavancin in gram-positive infections: effectiveness, safety and cost in clinical practice by Chamorro-De Vega, E, Rodriguez-Gonzalez, CG, Rochet, ME, Valerio, M, Olmedo, M, Herranz-Alonso, A, Munoz, P, Sanjurjo-Saez, M

“…BackgroundDalbavancin (DAL) has recently been approved to treat complicated skin and soft tissue infections. It enables treatments with a single IV…”
Get full text

4CPS-053 Study on daptomycin use as a first step towards an antimicrobial stewardship programme by García Sánchez, S, García-Moreno, FJ, Rodríguez-González, C, Chamorro-De Vega, E, García-Martín, E, Valerio Minero, M, Muñoz-García De Paredes, P, Bouza-Santiago, E, Herranz-Alonso, A, Sanjurjo-Sáez, M

“…BackgroundThe use of daptomycin has increased in Spain since its approval and there is a great variability in the dosage and the criteria for its use in…”
Get full text

CP-115 Second generation direct acting antiviral agents in post-transplant hepatitis c virus infection recurrence: Real clinical practice by Chamorro-De-Vega, E, Gomez-Marquez, AM, Gimenez-Manzorro, A, Romero-Jimenez, R, Rodriguez-Gonzalez, C, Martinez-Fernandez-Llamazares, C, Ibañez-Garcia, S, Tovar-Pozo, M, Herranz-Alonso, A, Sanjurjo-Saez, M

“…BackgroundPatients who have recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have substantial rates of morbidity and mortality…”
Get full text

CP-096 Final results of effectiveness and safety of direct acting antiviral agents in the treatment of chronic hepatitis c virus infection by Chamorro-De-Vega, E, Gimenez-Manzorro, A, Gomez-Marquez, AM, Monje-Garcia, B, Escudero-Vilaplana, V, Lallana-Sainz, E, Lobato-Matilla, ME, Revuelta-Herrero, JL, Herranz-Alonso, A, Sanjurjo-Saez, M

“…BackgroundDirect acting antivirals (DAAs) have become elective treatment for chronic hepatitis C virus (HCV) infection but final data regarding routine medical…”
Get full text

Assessment of new drugs in a tertiary hospital using a standardized tool by González-Bueno, J, Chamorro-de-Vega, E, Alfaro-Lara, E R, Galván-Banqueri, M, Santos-Ramos, B

“…To describe the profile of new drugs evaluated by the Pharmacy and Therapeutics committee in a tertiary hospital using a standardized tool, the Guideline for…”
Get more information